Sta Znaci PLATELET AGGREGATION na Hrvatskom - Hrvatski Prijevod

• agregaciju trombocita
• agregacije trombocita
• agregacija trombocita

Primjeri korištenja Platelet aggregation na Engleski i njihovi prijevodi na Hrvatskom

Vorapaxar inhibits thrombin-induced platelet aggregation in in vitro studies.
U ispitivanjima in vitro, vorapaksar inhibira trombinom induciranu agregaciju trombocita.

Platelet aggregation and bleeding time gradually returned to baseline values, generally within 5 days after treatment was discontinued.
Agregacija trombocita i vrijeme krvarenja postupno se vraćaju na početne vrijednosti, obično unutar 5 dana nakon prekida uzimanja lijeka.

Co-administration of heparin had no effect on the inhibition of platelet aggregation induced by clopidogrel.
Istodobna primijena heparina nije imala učinak na inhibiciju agregacije trombocita induciranu klopidogrelom.

If acetylsalicylic acid inhibits only platelet aggregation, the dipyridamole in addition inhibits platelet activation and adhesion.
Ako acetilsalicilna kiselina inhibira agregaciju trombocita samo, na dipyridamole dalje inhibira aktivaciju i adheziju leukocita.

Dynastat had no effect on acetylsalicylic acid-mediated inhibition of platelet aggregation or bleeding times.
Dynastat nije imao učinka na inhibiciju agregacije trombocita posredovanu acetilsalicilnom kiselinom ili na vrijeme krvarenja.

Protecting against heart disease, cancer, platelet aggregation, vessel flaccidity, decreasing blood fat and resisting mutagenesis, etc.
Štiti od srčanih bolesti, raka, agregacija trombocita, brod flaccidity, smanjuje masnoće u krvi i opiranje mutageneze, itd.

By limiting lipid oxidation, phenolics in grape seeds may reduce risk of heart disease, such as by inhibiting platelet aggregation and reducing inflammation.
Ograničavajući lipidnu oksidaciju, phenolics u sjemenkama grožđa može smanjiti rizik od srčanih bolesti, kao što inhibira agregaciju trombocita i smanjuje upale.

Higher inhibition of platelet aggregation was observed in patients switched to prasugrel 10 mg compared with those treated with clopidogrel 150 mg.
Veća inhibicija agregacije trombocita primijećena je u bolesnika prebačenih na prasugrel u dozi od 10 mg u odnosu na one liječene klopidogrelom u dozi od 150 mg.

It increases the inhibitory effect of aspirin and other NSAIDs kollagenindutsiruemuyu on platelet aggregation and increases the risk of bleeding incl.
To povećava inhibicijski učinak aspirina i drugih NSAID kollagenindutsiruemuyu na agregaciju trombocita i povećava rizik od krvarenja uključeno.

Prasugrel-mediated inhibition of platelet aggregation exhibits low between-subject(9%) and within-subject(12%) variability with both 5 µM and 20 µM ADP.
Prasugrelom posredovana inhibicija agregacije trombocita iskazuje nisku interindividualnu(9%) i intraindividualnu(12%) varijabilnost i uz 5 µm i uz 20 µm ADP-a.

If you suffer from thrombocytopenia(low platelet count- thrombocytopenia) with positive platelet aggregation test in vitro in the presence of enoxaparin sodium.
Ako bolujete od trombocitopenije(nizak broj trombocita) s pozitivnim testom agregacije trombocita in vitro u prisutnosti enoksaparinnatrija.

Inhibition of TRAP-induced platelet aggregation at a level of≥80% may last for 2 to 4 weeks after discontinuation of daily doses of vorapaxar sulfate 2.5 mg.
Inhibicija TRAP-om inducirane agregacije trombocita na razini od ≥ 80% može potrajati 2 do 4 tjedna nakon prekida primjene dnevne doze vorapaksarsulfata od 2, 5 mg.

A single intravenous bolus dose of unfractionated heparin(100 U/kg) did not significantly alter the prasugrel-mediated inhibition of platelet aggregation.
Jedna doza nefrakcioniranog heparina(100 U/kg) u obliku intravenske bolusne injekcije nije značajno promijenila prasugrelom posredovanu inhibiciju agregacije trombocita.

Pharmacotherapeutic group: Antithrombotic agent(platelet aggregation inhibitors excl. heparin), ATC code: B01AC16.
Farmakoterapijska skupina: Antitrombotički agens(inhibitor agregacije trombocita izuzev heparina), ATK oznaka: B01AC16.

The active thiol metabolite which has been isolated in vitro, binds rapidly and irreversibly to platelet receptors, thus inhibiting platelet aggregation.
Aktivni tiolni metabolit, koji je izoliran in vitro, brzo se i ireverzibilno veže na receptore na trombocitima i time inhibira agregaciju trombocita.

Pharmacotherapeutic group: Antithrombotic agents, platelet aggregation inhibitors excl. heparin, ATC code: B01AC04.
Farmakoterapijska skupina: Antitrombocitni agensi, inhibitori agregacije trombocita izuzev heparina, ATK oznaka: B01AC-04.

Elderly: In a study of healthy subjects between the ages of 20 and 80 years, age had no significant effect on pharmacokinetics of prasugrel or its inhibition of platelet aggregation.
Starije osobe: U ispitivanju zdravih ispitanika u dobi između 20 i 80 godina dob nije značajno utjecala na farmakokinetiku prasugrela ni njegovu inhibiciju agregacije trombocita.

Pharmacotherapeutic group: Antithrombotic agents, platelet aggregation inhibitors excluding heparin, ATC code: B01AC27.
Farmakoterapijska skupina: antitrombotski lijekovi, inhibitori agregacije trombocita izuzev heparina, ATK oznaka: B01AC27.

The agent inhibits platelet aggregation, restores the configuration properties in the outer membrane of rigid red blood cells, reduces the duration and severity of the nystagmus of the vestibular type.
Sredstvo inhibira agregaciju trombocita, vraća svojstva konfiguracije u krute vanjske membrane eritrocita, smanjuje trajanje i težinu vestibularne tipa nistagmus.

Activity and concentration of von Willebrand's antigen concentration as well as platelet aggregation induced by ristocetin for the diagnosis of von Willebrand's disease.
Ispitivanje aktivnosti i koncentracije antigena von Willebrandovog faktora, kao i agregacija trombocita indukovane ristocetinom za dijagnozu von Willebrand-ove bolesti.

The agent inhibits platelet aggregation, restores the configuration properties in the outer membrane of rigid red blood cells, reduces the duration and severity of the nystagmus of the vestibular type.
Agent inhibira agregaciju trombocita, vraća svojstva konfiguracije u vanjskoj membrani krutih crvenih krvnih stanica, smanjuje trajanje i težinu nistagusa vestibularnog tipa.

Ventricular, atrial fibrillation, pain in the chest and heart, heartbeat, breathlessness, Ad/hypotension, kaliopenia, inhibition of platelet aggregation(prolonged use), petehiale bleeding.
Klijetke, fibrilacija atrija, bol u prsima i prsa, otkucaj srca, daha, povišen krvni pritisak/ hipotenzija, kaliopenia, inhibicija agregacije trombocita(produljena primjena), petehialnim krvarenje.

Pharmacokinetics of prasugrel and its inhibition of platelet aggregation were similar in subjects with mild to moderate hepatic impairment compared to healthy subjects.
Farmakokinetika prasugrela i njegova inhibicija agregacije trombocita bile su podjednake u ispitanika s blagim do umjerenim oštećenjem jetre i zdravih ispitanika.

Ceftriaxone, suppressing intestinal flora, inhibits the synthesis of vitamin k. Therefore, while the use of drugs, reduces platelet aggregation(NSAIDs, salicilaty, sulfinpirazon), It increases the risk of bleeding.
Ceftriakson, suzbijanju crijevne flore, inhibira sintezu vitamina k. Stoga, uz korištenje lijekova, smanjuje agregaciju trombocita(NSAID, salicilaty, sulfinpirazon), Ona povećava rizik od krvarenja.

Eptifibatide reversibly inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor and other adhesive ligands to the glycoprotein(GP) IIb/IIIa receptors.
Eptifibatid reverzibilno inhibira agregaciju trombocita sprječavajući vezivanje fibrogena, von Willebrandovog faktora i drugih adhezivnih liganada za receptore glikoproteina(GP) IIb/IIIa.

Caution should be prescribed to patients, receiving treatment with drugs, increase the risk of bleeding(platelet aggregation inhibitors/ clopidogrel, ticlopidine/) or selective serotonin reuptake inhibitors.
Treba biti oprezan imenovati droge bolesnika, koji primaju lijekove za liječenje, povećati rizik od krvarenja(agregacija trombocita inhibitori/Klopidogrel, Tiklopidin/) ili selektivni serotonin inhibitori.

Acetylsalicylic acid inhibits platelet aggregation by irreversible inhibition of prostaglandin cyclo-oxygenase and thus inhibits the generation of thromboxane A2, an inducer of platelet aggregation and vasoconstriction.
Acetilsalicilatna kiselina inhibira agregaciju trombocita ireverzibilnom inhibicijom prostaglandin ciklo-oksigenaze i time inhibira stvaranje tromboksana A2, induktora agregacije trombocita i vazokonstrikcije.

Other functional aspects also protect T lymphocytes, protect red blood cells, resist free radical oxidation, inhibit platelet aggregation and reduce the risk of myocardial infarction and cerebral infarction.
Drugi funkcionalni aspekti također štite T limfocite, štite crvene krvne stanice, odupiru oksidaciji slobodnih radikala, inhibiraju agregaciju trombocita i smanjuju rizik od infarkta miokarda i moždanog infarkta.

Acetylsalicylic acid inhibits platelet aggregation by irreversible inhibition of prostaglandin cyclo-oxygenase and thus inhibits the generation of thromboxane A2, an inducer of platelet aggregation and vasoconstriction.
Acetilsalicilatna kiselina(ASK) inhibira agregaciju trombocita ireverzibilnom inhibicijom enzima prostaglandin ciklooksigenaze, čime sprječava stvaranje tromboksana A2, koji potiče agregaciju trombocita i vazokonstrikciju.

Blood gases abnormal*, Electrocardiogram abnormalities(inc QT prolongation)*, International normalised ratio abnormal*, Gastric pH decreased, Platelet aggregation increased, Troponin I increased, Virus identification and serology*, Urine analysis abnormal.
Abnormalni plinovi u krvi*, abnormalnosti elektrokardiograma(uključujući QT produljenje)*, abnormalan međunarodni normalizirani omjer(INR)*, snižen pH želuca, povećana agregacija trombocita, povišen troponin I, identifikacija virusa i serologija*, abnormalan nalaz urina.